Ricki Levitus

Ricki Levitus, on behalf of Subbu Nambi, asked about market share changes in the Women's Health market in 2025 and what the 2026 guidance assumes regarding further market share gains.

Answer

Steve Chapman (CEO, Natera) stated that Natera had a record year in Women's Health in 2025 and a strong start in Q1 2026. He attributed this success partly to the new 21-gene Fetal Focus test, which has opened opportunities to acquire new customers. While Natera does not have specific data on competitors' market share, the company is growing its business and seeing record numbers.

Ricki Levitus, on behalf of Subbu Nambi, asked about Natera's market share changes in the women's health market in 2025 and the assumptions for further market share gains embedded in the guidance and volume comments for women's health.

Answer

Steve Chapman (CEO, Natera) stated that Natera had a record year in women's health in 2025 and a strong start in Q1 2026, even before the launch of the 21-gene Fetal Focus test. He noted that the new Fetal Focus test is now creating opportunities to acquire new customers, and while they don't have data on competitors' share, Natera is growing its business and seeing record numbers.

Ricki Levitus of Guggenheim Partners, on for Subbu Namdi, asked about the performance of the SneakPeek test and its success in funneling patients to Prequel. She also asked for clarification on what is incrementally new in the strategic plan for the Women's Health and Mental Health businesses.

Answer

President and CEO Sam Raha acknowledged that the SneakPeek business has been a 'challenge' and is not a primary area of focus at this time. Regarding the strategic update, he explained that for Women's Health and Mental Health, the key change is a 'deliberate' and disciplined approach to resourcing and investment. The goal is to maintain growth at or above market rates in these areas while prioritizing capital and focus on the higher-growth Cancer Care Continuum pillar.

Ricki Levitus, on for Subbu Nambi, asked for an update on the competitive landscape for DecisionDx-Melanoma, particularly in light of new data and partnerships from competitor SkylineDx.

Answer

CEO Derek Maetzold stated that Castle has not seen meaningful competitive traction from SkylineDx over the last four years. He critically pointed out that Skyline's recent study data showed a 7.1% sentinel lymph node positivity rate in its low-risk group, which is above the key 5% clinical threshold. He contrasted this with Castle's test, which studies have shown achieves a rate below that important threshold.